Capitalize on the secular growth in weight-loss pharmaceuticals by taking a position in Novo Nordisk (NVO) as expanding telehealth adoption and oral formulations accelerate demand for treatments like Wegovy. Complement drug manufacturers with digital health platforms like Hims & Hers Health (HIMS), which is rapidly capturing market share through direct-to-consumer access and home delivery of high-demand weight-loss programs. To hedge against persistent U.S. debt expansion and long-term structural inflation, allocate a portion of your portfolio to hard assets and inflation-protected assets. Additionally, maintain exposure to commodities and broad energy sector funds to protect against ongoing fuel price volatility and supply chain pressures.

U.S. Macro & Sovereign Debt

• Donald Trump proposed a $5,000 dividend for every American adult if Republicans win the midterms, estimated to cost $1.3 trillion with no specified revenue offset.
  • Galloway argued that adding debt at roughly 6% interest places a compounding burden on future generations ($5,000 today becomes ~$13,000 per child in 18 years).
  • Overall U.S. fiscal debt has surged from $7 trillion under George W. Bush to approximately $40 trillion across subsequent administrations.
  • History shows fiat currencies fail when democracies run persistent deficits, creating long-term risks of high inflation and sovereign credit pressure.
  • Proposed structural fixes: capping deficit growth below GDP growth, narrowing capital gains tax deductions, eliminating $2.25 trillion in tax loopholes, closing the $750 billion IRS tax gap, raising the Social Security eligibility age, and lowering Medicare eligibility to reduce healthcare costs.

Takeaways

• Prepare for long-term structural inflation and potential upward pressure on interest rates by maintaining a diversified portfolio that includes inflation-protected assets or hard assets.
• Monitor federal deficit growth and credit rating downgrades, which could impact bond yields and broader equity valuations.

Novo Nordisk A/S (NVO) / GLP-1 Weight Loss Drugs

• Advertised as a partner treatment via telehealth, featuring Wegovy (semaglutide) as an effective treatment capable of reducing up to 20% of body weight when paired with diet and exercise.
  • Mentioned the availability of oral GLP-1 pill formulations, reducing the barrier of needle-based injections.

Takeaways

• GLP-1 pharmaceuticals remain a major secular growth theme within the healthcare and biotech sectors.
• Keep an eye on oral administration methods and expansion into telehealth channels as a primary driver for broader consumer adoption and market penetration.

Hims & Hers Health, Inc. (HIMS)

• Highlighted as a direct-to-consumer platform providing weight management programs, GLP-1 access, and remote consultations with licensed healthcare providers.
  • Emphasized convenience with end-to-end online visits and direct-to-door delivery.

Takeaways

• The digital health and telehealth sector continues to capture market share in high-demand categories like weight loss and chronic care management.
• Evaluate telehealth providers based on their ability to secure consistent drug supply and navigate state-level regulatory restrictions.

Energy & Commodities

• Mentioned political claims regarding energy pricing, specifically guarantees of gas dropping below $2.00 per gallon and political debates shifting around $6.00 diesel.
  • Current energy and diesel costs remain a sensitive macroeconomic and inflation indicator affecting consumer sentiment and operational costs across industries.

Takeaways

• Maintain exposure to broad energy sector funds or commodities to hedge against geopolitical tensions and supply chain bottlenecks that drive transportation and diesel costs higher.